🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Hepatocellular Carcinoma Non-resectable

Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study NCT07806292Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: anlotinib combined with benmelstobart and HAIC Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma NCT06911255Phase 1, Phase 21 site📍 Seoul Yoon Jun Kim · Tests: Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE) Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC NCT06726161Phase 1, Phase 213 sites📍 Birmingham📍 Phoenix📍 Orange RayzeBio, Inc. · Tests: RYZ811, RYZ801 SIRT Versus cTACE for Unresectable HCC (CHANCE2506) NCT06909708NA1 site📍 Nanjing Zhongda Hospital · Tests: SIRT, cTACE Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma NCT06339424Phase 21 site📍 Taoyuan City Chang Gung Memorial Hospital · Tests: Atezolizumab, Bevacizumab, Photon radiotherapy Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma NCT06406634Phase 21 site📍 Changsha Hunan Cancer Hospital · Tests: Cadonilimab, Lenvatinib Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study NCT07305428NA1 site📍 Hong Kong The University of Hong Kong · Tests: Stereotactic Body Radiation Therapy followed by Immunotherapy Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma NCT06133062Phase 21 site📍 Taoyuan City Chang Gung Memorial Hospital · Tests: Atezolizumab, Bevacizumab, Proton radiotherapy Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial NCT05751343Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: TACE-HACI, plus atezolizumab-bevacizumab A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment. NCT07490262Phase 2, Phase 32 sites📍 Hefei📍 Shanghai Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Tests: Bevacizumab, Capecitabine, Oxaliplatin, IBI310, Sintilimab A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma NCT05440708Phase 1, Phase 221 sites📍 Birmingham📍 La Jolla📍 Los Angeles Tvardi Therapeutics, Incorporated · Tests: TTI-101, Pembrolizumab, Atezolizumab, Bevacizumab Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer NCT03942328Phase 1, Phase 21 site📍 Rochester Mayo Clinic · Tests: Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine Peg IFNα-2b Therapy for Unresectable Mid to Late Stage HBV-HCC NCT07769827NA1 site📍 Nanjing Jinling Hospital, China · Tests: Combined Peg IFNα-2b treatment group MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. NCT07391839Phase 18 sites📍 Hefei📍 Fuzhou📍 Guangzhou Suzhou Mednovo Yi Medical Technology Co., Ltd. · Tests: MDN-001 Injection(Yttrium-90 Microsphere Injection) Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment NCT07238881Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Dalpiciclib Isetionate Tablets, Dalpiciclib Isetionate Tablets, Camrelizumab (anti-PD-1 inhibitor) Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC NCT06397222Phase 21 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Sin-Bev-SIRT Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT NCT06904183Phase 21 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: LEN+SIN+DEB-TACE+HAIC, LEN+SIN+DEB-TACE Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma NCT07176650Phase 151 sites📍 Glendale📍 Glendale📍 Jacksonville Shanghai Henlius Biotech · Tests: HLX13, Yervoy, OPDIVO Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642n/a3 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Tissue Collection DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC NCT06397235Phase 21 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: DEB-TACE+HAIC, DEB-TACE Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma NCT07099274Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: lparomlimab and Tuvonralimab Injection in Combination with TACE and Lenvatinib Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry) NCT05967143n/a9 sites📍 Clichy📍 Créteil📍 Pierre-Bénite Sirtex Medical · Tests: SIRT HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma NCT06244225Phase 21 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: Donafenib； Sintilimab； HAIC Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC NCT05608213Phase 31 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: Lenvatinib Plus I-125 Seed Brachytherapy, Lenvatinib Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma NCT06446154Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Fruquintinib Oral Zinc Supplementation Combined With Targeted Immunotherapy for Unresectable or Advanced Hepatocellular Carcinoma NCT07793695Phase 21 site📍 Hefei Anhui Provincial Hospital · Tests: Oral elemental zinc supplementation, 20 mg/day, Oral elemental zinc supplementation, 30 mg/day, Standard-of-care target… Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH) NCT07293468Phase 2, Phase 31 site📍 Hong Kong Tuen Mun Hospital · Tests: Transarterial chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), SIRT Yttrium-90, Atezolizumab &… Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension NCT06280313n/a1 site📍 Wuhan Zhiyong Huang · Tests: Splenectomy+Targeted therapy+ Immunotherapy HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma NCT06187961Phase 21 site📍 Wuhan Tongji Hospital · Tests: Hepatic arterial infusion chemotherapy (HAIC-FOLFOX), Lenvatinib, Cadonilimab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy